CORONA Remedies Limited has formally notified stock exchanges about an upcoming board meeting scheduled to review its quarterly financial performance. The pharmaceutical company will present its third quarter results for the fiscal year 2026, marking a significant milestone in its financial reporting calendar.

Board Meeting Details

The company has scheduled its Board of Directors meeting for Monday, February 02, 2026, in compliance with regulatory requirements. The meeting agenda includes several key items for consideration and approval:

The board will consider and approve the unaudited financial results for both standalone and consolidated operations. Additionally, the directors will address other business matters as deemed necessary during the session.

Trading Window Restrictions

In accordance with the company's Code of Conduct for Regulating, Monitoring and Reporting of Insider Trading, CORONA Remedies has implemented trading restrictions on its securities. The trading window closure was initially communicated through a letter dated December 29, 2025.

Regulatory Compliance

The notification has been submitted to both major stock exchanges where the company's shares are listed. CORONA Remedies maintains compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, particularly Regulation 29 and other applicable provisions.

The formal communication was digitally signed by Chetna Dharajiya, Company Secretary and Compliance Officer, on January 27, 2026. This advance notice ensures transparency and provides adequate time for stakeholders to prepare for the financial results announcement.

Corona Remedies has secured a significant regulatory milestone by obtaining a Good Manufacturing Practices (GMP) compliance certificate from the Eurasian Economic Union (EAEU) for its manufacturing facility located in Gujarat.

Regulatory Achievement Details

The GMP compliance certificate represents formal recognition of Corona Remedies' adherence to international manufacturing standards and quality protocols at its Gujarat facility. This certification validates the company's manufacturing processes, quality control systems, and operational procedures meet EAEU's stringent regulatory requirements.

Strategic Implications

The EAEU GMP certificate enhances Corona Remedies' regulatory portfolio and demonstrates the company's commitment to maintaining international quality standards. This certification potentially facilitates market access opportunities within EAEU member countries, which include Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan.

The Gujarat facility's compliance with EAEU standards reflects Corona Remedies' focus on meeting diverse international regulatory requirements, strengthening its position in global pharmaceutical markets.